Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

4.08
-0.1900-4.45%
Post-market: 4.130.0500+1.23%19:57 EDT
Volume:547.18K
Turnover:2.17M
Market Cap:6.66M
PE:-0.22
High:4.70
Open:3.79
Low:3.65
Close:4.27
52wk High:71.50
52wk Low:3.18
Shares:1.63M
Float Shares:1.20M
Volume Ratio:33.38
T/O Rate:45.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:2.08
PE(LYR):-0.07

Loading ...

Ernexa Therapeutics - no Complete Tumor Clearance Observed with Erna-101 or Anti-pd-1 Monotherapy

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics CEO Corner Highlights Differentiated Erna-101 Platform as Company Advances Toward Planned First-in-human Phase 1 Study in 2026

THOMSON REUTERS
·
Jul 14

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

GlobeNewswire
·
Jul 14

Ernexa Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Jul 03

Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3

Reuters
·
Jun 27

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

GlobeNewswire
·
Jun 25

Ernexa expects FDA review of ERNA-101 IND in Q4 2026

Reuters
·
Jun 17

Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026

THOMSON REUTERS
·
Jun 17

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

GlobeNewswire
·
Jun 17

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

GlobeNewswire
·
Jun 09

Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3

TIPRANKS
·
May 27

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

GlobeNewswire
·
May 27

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

GlobeNewswire
·
May 20

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:42 PM

Reuters
·
May 16

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM

Reuters
·
May 12

Ernexa Therapeutics announces annual shareholder meeting

Reuters
·
May 12

Ernexa Q1 net loss narrows 32.87% to $5.51 million; no revenue

Reuters
·
May 12

Ernexa Therapeutics to join Virtual Investor Closing Bell event

Reuters
·
May 11

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

GlobeNewswire
·
May 11

Ernexa Therapeutics initiated with a Buy at Brookline

TIPRANKS
·
May 08